WO2004014357A3 - Utilisation therapeutique de derives d'acide amine d'aryle - Google Patents

Utilisation therapeutique de derives d'acide amine d'aryle Download PDF

Info

Publication number
WO2004014357A3
WO2004014357A3 PCT/IB2003/003193 IB0303193W WO2004014357A3 WO 2004014357 A3 WO2004014357 A3 WO 2004014357A3 IB 0303193 W IB0303193 W IB 0303193W WO 2004014357 A3 WO2004014357 A3 WO 2004014357A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid derivatives
therapeutic use
disorders
aryl amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/003193
Other languages
English (en)
Other versions
WO2004014357A2 (fr
Inventor
Graham Nigel Maw
David James Rawson
Lisa Rosemary Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Ltd Great Britain
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Pfizer Inc filed Critical Pfizer Ltd Great Britain
Priority to JP2004527144A priority Critical patent/JP2006507238A/ja
Priority to AU2003247056A priority patent/AU2003247056A1/en
Priority to MXPA05001534A priority patent/MXPA05001534A/es
Priority to BR0313284-6A priority patent/BR0313284A/pt
Priority to CA002495108A priority patent/CA2495108A1/fr
Priority to EP03784335A priority patent/EP1528919A2/fr
Publication of WO2004014357A2 publication Critical patent/WO2004014357A2/fr
Publication of WO2004014357A3 publication Critical patent/WO2004014357A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

Selon cette invention, les composés de formule (I) sont utilisés dans le traitement d'attaques de lipothymie, d'hypocinésie, de troubles crâniens, de troubles neurodégénératifs, de dépression, d'anxiété, de panique, de douleurs neuropathiques, de troubles neuropathologiques et de troubles du sommeil. Ladite invention a aussi trait à des processus de préparation des produits finaux et d'intermédiaires utilisés dans le traitement, ainsi que des compositions pharmaceutiques renfermant au moins un desdits composés.
PCT/IB2003/003193 2002-08-09 2003-07-29 Utilisation therapeutique de derives d'acide amine d'aryle Ceased WO2004014357A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004527144A JP2006507238A (ja) 2002-08-09 2003-07-29 アリールアミノ酸誘導体の治療的使用
AU2003247056A AU2003247056A1 (en) 2002-08-09 2003-07-29 Therapeutic use of aryl amino acid derivatives
MXPA05001534A MXPA05001534A (es) 2002-08-09 2003-07-29 Uso terapeutico de derivados arilo de aminoacidos.
BR0313284-6A BR0313284A (pt) 2002-08-09 2003-07-29 Utilização terapêutica de derivados de aril-aminoácidos
CA002495108A CA2495108A1 (fr) 2002-08-09 2003-07-29 Utilisation therapeutique de derives d'acide amine d'aryle
EP03784335A EP1528919A2 (fr) 2002-08-09 2003-07-29 Utilisation therapeutique de derives d'acide amine d'aryle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218590.8A GB0218590D0 (en) 2002-08-09 2002-08-09 Therapeutic use of aryl amino acid derivatives
GB0218590.8 2002-08-09

Publications (2)

Publication Number Publication Date
WO2004014357A2 WO2004014357A2 (fr) 2004-02-19
WO2004014357A3 true WO2004014357A3 (fr) 2004-07-01

Family

ID=9942061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003193 Ceased WO2004014357A2 (fr) 2002-08-09 2003-07-29 Utilisation therapeutique de derives d'acide amine d'aryle

Country Status (8)

Country Link
EP (1) EP1528919A2 (fr)
JP (1) JP2006507238A (fr)
AU (1) AU2003247056A1 (fr)
BR (1) BR0313284A (fr)
CA (1) CA2495108A1 (fr)
GB (1) GB0218590D0 (fr)
MX (1) MXPA05001534A (fr)
WO (1) WO2004014357A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031194A1 (fr) * 1994-05-11 1995-11-23 Shapiro Howard K Compositions pour le traitement de maladies inflammatoires chroniques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031194A1 (fr) * 1994-05-11 1995-11-23 Shapiro Howard K Compositions pour le traitement de maladies inflammatoires chroniques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEE N S ET AL: "The novel anti-convulsant drug, Gabapentin (NEURONTIN), BINDS TO THE ALPHA.2.DELTA SUBUNIT OF A CALCIUM CHANNEL", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5768 - 5776, XP002240620, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
GB0218590D0 (en) 2002-09-18
EP1528919A2 (fr) 2005-05-11
WO2004014357A2 (fr) 2004-02-19
BR0313284A (pt) 2005-07-12
MXPA05001534A (es) 2005-04-19
AU2003247056A1 (en) 2004-02-25
JP2006507238A (ja) 2006-03-02
CA2495108A1 (fr) 2004-02-19

Similar Documents

Publication Publication Date Title
UA49011C2 (uk) Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
AP2002002517A0 (en) Bicyclic amino acids as pharmaceutical agents.
MY134865A (en) Fused bicyclic or tricyclic amino acids
NO983612L (no) Nye cykliske aminosyrer som farmas°ytiske midler
WO2006037982A3 (fr) Nouveaux composes
WO2004099171A3 (fr) Acides amino-carboxyliques substitues
MY139541A (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AU4673300A (en) Amino heterocycles useful as pharmaceutical agents
WO2003087062A3 (fr) Composes heterocycliques, procede de preparation de ces composes et compositions pharmaceutiques les contenant, et utilisations en medecine
WO2002042256A3 (fr) Composes gaba n-alkyles, procedes de preparation et utilisations comme medicaments
WO2004014357A3 (fr) Utilisation therapeutique de derives d'acide amine d'aryle
WO2004016583A8 (fr) Derives de glycine substitues servant de medicaments
CA2245647A1 (fr) Nouveaux aminoacides cycliques pontes utilises comme agents pharmaceutiques
HK1085720A1 (en) Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003784335

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2495108

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001534

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004527144

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003784335

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003784335

Country of ref document: EP